18 recruiting, 5 completed, 4 not yet recruiting, 3 active not recruiting. 18 Phase 2, 12 Phase 1, 3 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Hormone Receptor-Positive Breast Cancer: new trials by email Literature Review of Hormone Receptor-Positive Breast Cancer trials Research Report on Hormone Receptor-Positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers Stereotactic Radiation Therapy, Endocrine Therapy - Breast Cancer, Early-Stage Breast Carcinoma | Not applicable | Not yet recruiting | Renaissance Institute of Precision Oncology and Radiosurgery | 30 | 2027-01-01 | 2026-09-28 |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 240 | 2026-10-01 | 2026-07-21 |
| Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Culmerciclib, Aromatase Inhibitor (AI) - Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-09-14 | 2026-09-15 |
| Estradiol Levels According to Body Mass Index in Premenopausal Patients With Breast Cancer Hormone Receptor-Positive Breast Cancer | Not yet recruiting | D'Or Institute for Research and Education | 172 | 2026-09-03 | 2026-09-22 | |
| CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment CDK4/6 inhibitor with endocrine therapy - Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer | Phase 2 | Recruiting | Peking University People's Hospital | 158 | 2026-04-20 | 2026-07-13 |
| A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer True Acupuncture, Sham Acupuncture - Acupuncture Treatment, Hormone Receptor-Positive Breast Cancer | Not applicable | Not yet recruiting | Peking University People's Hospital | 60 | 2026-04-01 | 2026-03-19 |
| Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea Breast Neoplasms, Hormone Receptor-Positive Breast Cancer | Recruiting | Hubei Cancer Hospital | 60 | 2025-12-21 | 2026-04-03 | |
| Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer CDK4/6 Inhibitors, Anti-HER2 Therapy, Standard Breast Cancer Treatment - Breast Neoplasms, Triple Negative Breast Neoplasms | Recruiting | Fundación Santa Fe de Bogota | 370 | 2025-12-01 | 2026-10-02 | |
| ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy - Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer | Phase 2 | Recruiting | Peking University People's Hospital | 393 | 2025-08-01 | 2026-07-13 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer Two Component Product CLBR001 + ABBV-461 - Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC) | Phase 1 | Terminated | Calibr, a division of Scripps Research | 10 | 2025-04-17 | 2026-05-28 |
| Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer Tirzepatide - Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 40 | 2024-10-30 | 2026-01-21 |
| ETHAN - ET for Male BC Tamoxifen, Anastrozole, Degarelix - Male Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 2 | Recruiting | Jose Pablo Leone | 60 | 2023-10-11 | 2026-08-24 |
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study Palbociclib, Ribociclib, Abemaciclib - Breast Adenocarcinoma, Breast Cancer Stage IV | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 3500 | 2023-05-01 | 2025-02-03 | |
| Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer Paclitaxel, Carboplatin, Trastuzumab - Breast Cancer, Breast Neoplasm | Phase 2 | Recruiting | Baylor Breast Care Center | 185 | 2023-04-18 | 2025-02-27 |
| Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Fasting Mimicking diet program - Fasting Mimicking Diet, HER2-negative Breast Cancer | Phase 3 | Suspended | Leiden University Medical Center | 10 | 2023-03-17 | 2023-11-22 |
| VS-6766+Abema+Fulv in Met HR+/HER- BC VS-6766, Abemaciclib, Fulvestrant - Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Adrienne G. Waks | 63 | 2023-02-23 | 2026-04-30 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer EP0062, Elacestrant, Everolimus - Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Ellipses Pharma | 95 | 2023-01-11 | 2026-06-22 |
| Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd Metastatic Breast Cancer, Drug Resistance | Recruiting | Hunan Cancer Hospital | 200 | 2023-01-01 | 2025-07-18 |
Showing 20 of 37. Sign in to see all of them.
Breast Neoplasms (24) · Triple Negative Breast Neoplasms (9) · Neoplasm Metastasis (4) · Endometrial Neoplasms (3) · Breast Neoplasms, Male (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Ovarian Epithelial (2) · Adenocarcinoma (1) · Breast Diseases (1) · COVID-19 (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Glioblastoma (1)
Neoplasms (28) · Neoplasms by Site (28) · Skin Diseases (27) · Skin and Connective Tissue Diseases (27) · Breast Diseases (26) · Pathological Conditions, Signs and Symptoms (7) · Carcinoma (4) · Lung Diseases (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Neoplastic Processes (4) · Pathologic Processes (4) · Respiratory Tract Diseases (4) · Adnexal Diseases (3) · Breast Neoplasms (3)
abemaciclib (8) · Fulvestrant (5) · ribociclib (5) · Anastrozole (4) · Letrozole (4) · palbociclib (4) · Paclitaxel (3) · Trastuzumab (3) · pertuzumab (3) · Aromatase Inhibitors (2) · Tamoxifen (2) · exemestane (2) · pyrotinib (2) · ALX148 (1) · Ado-Trastuzumab Emtansine (1)
Peking University People's Hospital (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Fudan University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · QuantumLeap Healthcare Collaborative (2) · Adrienne G. Waks (1) · Baylor Breast Care Center (1) · Calibr, a division of Scripps Research (1) · Celgene (1) · D'Or Institute for Research and Education (1) · Ellipses Pharma (1) · Exelixis (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fundación Santa Fe de Bogota (1) · Gun Oh Chong (1)
United States (17) · China (9) · Spain (3) · United Kingdom (3) · France (2) · Italy (2) · Netherlands (2) · South Korea (2) · Australia (1) · Belgium (1) · Canada (1) · Colombia (1) · Germany (1) · India (1) · Japan (1)
Paula R Pohlmann, MD, MSc, PhD (2) · Adrienne G Waks, MD (1) · Aixa E Soyano Muller, MD (1) · Andreas Schneeweiss, MD, Prof. (1) · Anthony Elias, MD (1) · Chang Gong (1) · Coral Omene, MD., PhD (1) · Funda Meric-Burnstam, MD (1) · Gong Chang, doctor (1) · Hyeong-Gon Moon (1) · Jose Pablo Leone, MD (1)
PMID 16622270, PMID 18997125, PMID 24529560, PMID 26297356, PMID 28135148, PMID 30307466, PMID 31838010, PMID 32330069, PMID 33507815, PMID 34902335, PMID 35020204, PMID 35337692, PMID 36821125, PMID 38751537, PMID 39851040, PMID 41413016, PMID 42688140